Evidence map›Paper›PMID 25483071›Full record

ArticleCell cycle (Georgetown, Tex.)2015

Cdt2-mediated XPG degradation promotes gap-filling DNA synthesis in nucleotide excision repair.

Chunhua Han, Gulzar Wani, Ran Zhao, Jiang Qian, Nidhi Sharma, Jinshan He, Qianzheng Zhu, Qi-En Wang, Altaf A Wani

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Revisiting the Function of p21International journal of molecular sciences · 2022
    Review
  4. XPG: a multitasking genome caretaker.Cellular and molecular life sciences : CMLS · 2022
    Review
  5. Article
  6. Regulation of DNA Replication Licensing and Re-Replication by Cdt1.International journal of molecular sciences · 2021
    Review
  7. CRL4AOncogene · 2021
    Article
  8. Article
  9. Review
  10. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.Biochimica et biophysica acta. Reviews on cancer · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. PostExcision Events in Human Nucleotide Excision Repair.Photochemistry and photobiology · 2017
    Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chunhua Hana Department of Radiology ; The Ohio State University Wexner Medical Center ; Columbus , OH USA.
Gulzar Wani
Ran Zhao
Jiang Qian
Nidhi Sharma
Jinshan He
Qianzheng Zhu
Qi-En Wang
Altaf A Wani
The Ohio State University Wexner Medical Center · USColumbus Oncology and Hematology Associates · USComprehensive Blood & Cancer Center · US

Funding

Cross-talking pre-incision events of eukaryotic NERR01ES012991 · NIEHS · OHIO STATE UNIVERSITY · PI WANI, ALTAF A, ZHU, QIANZHENG · 2004 to 2020
$6.2M
DNA DAMAGE RESPONSES FOLLOWING GENOTOXIN EXPOSURER01ES002388 · NIEHS · OHIO STATE UNIVERSITY · PI WANI, ALTAF A · 1985 to 2016
$4.9M
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistanceR01CA151248 · NCI · OHIO STATE UNIVERSITY · PI WANG, QIEN · 2011 to 2014
$990k
NCI NIH HHS CA151248NIEHS NIH HHS ES002388NIEHS NIH HHS R01 ES002388NIEHS NIH HHS R01 ES012991
6 · The paper itself

Abstract

Xeroderma pigmentosum group G (XPG) protein is a structure-specific repair endonuclease, which cleaves DNA strands on the 3' side of the DNA damage during nucleotide excision repair (NER). XPG also plays a crucial role in initiating DNA repair synthesis through recruitment of PCNA to the repair sites. However, the fate of XPG protein subsequent to the excision of DNA damage has remained unresolved. Here, we show that XPG, following its action on bulky lesions resulting from exposures to UV irradiation and cisplatin, is subjected to proteasome-mediated proteolytic degradation. Productive NER processing is required for XPG degradation as both UV and cisplatin treatment-induced XPG degradation is compromised in NER-deficient XP-A, XP-B, XP-C, and XP-F cells. In addition, the NER-related XPG degradation requires Cdt2, a component of an E3 ubiquitin ligase, CRL4(Cdt2). Micropore local UV irradiation and in situ Proximity Ligation assays demonstrated that Cdt2 is recruited to the UV-damage sites and interacts with XPG in the presence of PCNA. Importantly, Cdt2-mediated XPG degradation is crucial to the subsequent recruitment of DNA polymerase δ and DNA repair synthesis. Collectively, our data support the idea of PCNA recruitment to damage sites which occurs in conjunction with XPG, recognition of the PCNA-bound XPG by CRL4(Cdt2) for specific ubiquitylation and finally the protein degradation. In essence, XPG elimination from DNA damage sites clears the chromatin space needed for the subsequent recruitment of DNA polymerase δ to the damage site and completion of gap-filling DNA synthesis during the final stage of NER.

Indexed as

DNA RepairCisplatinDNA-Binding ProteinsDNA DamageDNA Excision Repair Protein ERCC-5DNA Polymerase IIIEndonucleasesHeLa CellsHumansLeupeptinsNuclear ProteinsProliferating Cell Nuclear AntigenProteasome Endopeptidase ComplexProteasome InhibitorsProteolysisTranscription Factorsbenzyloxycarbonylleucyl-leucyl-leucine aldehydeCisplatinDDB2 protein, humanDNA-Binding ProteinsDNA Excision Repair Protein ERCC-5DNA Polymerase IIIDTL protein, humanEndonucleasesLeupeptinsNuclear ProteinsProliferating Cell Nuclear AntigenProteasome Endopeptidase ComplexProteasome InhibitorsTranscription FactorsUbiquitin-Protein LigasesCdt2CRL4gap-filling DNA synthesisnucleotide excision repairPCNAprotein degradationubiquitylationXPG

Identifiers

PMID25483071
PMCPMC4614405
OpenAlexW1989411691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.